Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 15/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 13/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | TSPO | P30536 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL536350 | 0.88 | F13A1 (0.50) | FFAR1FFAR4HDAC1HDAC8 | |
| SCHEMBL30427892 | 0.88 | F13A1 (0.50) | FFAR1FFAR4HDAC1HDAC8 | |
| SCHEMBL22668008 | 0.86 | FFAR1 (0.47) | NPSR1FFAR1FFAR4POLBPKM | |
| SCHEMBL26633682 | 0.86 | F13A1 (0.58) | NPSR1FFAR1FFAR4HDAC1HDAC8 | |
| SCHEMBL20185961 | 0.84 | HDAC1 (0.44) | NPSR1FFAR1FFAR4HDAC1HDAC8 | |
| SCHEMBL25213812 | 0.84 | FFAR1 (0.50) | NPSR1FFAR1FFAR4POLBPKM | |
| SCHEMBL15632913 | 0.84 | FFAR1 (0.46) | NPSR1FFAR1FFAR4POLB | |
| SCHEMBL27898388 | 0.84 | MMP12 (0.42) | NPSR1FFAR1FFAR4HDAC1HDAC8 | |
| SCHEMBL28259923 | 0.84 | F13A1 (0.61) | HDAC1HDAC8 | |
| SCHEMBL18602041 | 0.83 | FFAR1 (0.49) | NPSR1FFAR1FFAR4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2024-04-11 | — | — | US | disclosed |
| US-20230339913-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339913-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2023-10-26 | — | — | US | disclosed |
| EP-4192828-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | Nura Bio, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-110577542-A | Preparation method of sitagliptin | 南京奇可药业有限公司 | 2019-12-17 | — | — | CN | disclosed |
| US-8912327-B2 | Process for the production of sitagliptin | CHEMO IBERICA, S.A. (ES) | 2014-12-16 | — | — | US | disclosed |
| US-8912327-B2 | Process for the production of sitagliptin | CHEMO IBERICA, S.A. (ES) | 2014-12-16 | — | — | US | disclosed |
| US-8912327-B2 | Process for the production of sitagliptin | CHEMO IBERICA, S.A. (ES) | 2014-12-16 | — | — | US | disclosed |
| US-20140081026-A1 | PROCESS FOR THE PRODUCTION OF SITAGLIPTIN | CHEMO IBERICA S.A. (ES) | 2014-03-20 | — | — | US | disclosed |
| EP-2705026-A1 | PROCESS FOR THE PRODUCTION OF SITAGLIPTIN | Chemo Iberica, S.A. (ES) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012150328-A1 | PROCESS FOR THE PRODUCTION OF SITAGLIPTIN | CHEMO IBERICA, S.A. (ES) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012150328-A1 | PROCESS FOR THE PRODUCTION OF SITAGLIPTIN | CHEMO IBERICA, S.A. (ES) | 2012-11-08 | — | — | WO | disclosed |
| EP-1337517-B1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2008-11-26 | — | — | EP | disclosed |
| US-7244722-B2 | Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones | BIOVITRUM AB (SE) | 2007-07-17 | — | — | US | disclosed |
| EP-1534391-B1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| EP-1534391-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | Biovitrum AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040063693-A1 | Compounds | BIOVITRUM AB (SE) | 2004-04-01 | — | — | US | disclosed |
| WO-2004009586-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | NPSR1 4397/4885FFAR1 4246/4885FFAR4 4580/4885 |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | NPSR1 4397/4885FFAR1 4246/4885FFAR4 4580/4885 |
| US-20230339913-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | NPSR1 4397/4885FFAR1 4246/4885FFAR4 4580/4885 |
| US-20040063693-A1 | Compounds | HTR1A, HTR1B, HTR2C | NPSR1 32/4885FFAR1 146/4885FFAR4 197/4885 |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | NPSR1 4397/4885FFAR1 4246/4885FFAR4 4580/4885 |
| US-20140081026-A1 | PROCESS FOR THE PRODUCTION OF SITAGLIPTIN | DPP4, DPP7, DPP3 | NPSR1 2925/4885FFAR1 985/4885FFAR4 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.